LLY
Eli Lilly and Company
1,152.40$
+1.3%
vs. previous close
Closing price · As of: Sep 17, 2026
Statements
Income Statement
Eli Lilly and Company (LLY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 22,974 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,499 | 9,353 | 8,768 | 11,303 | 11,439 | 13,533 | 12,729 | 15,558 | 17,601 | 19,292 | 19,799 | 22,974 | 79,666 | |
| 1,860 | 1,788 | 1,674 | 2,170 | 2,171 | 2,404 | 2,224 | 2,448 | 3,008 | 2,884 | 3,577 | 3,268 | 12,737 | |
| 7,639 | 7,565 | 7,095 | 9,133 | 9,268 | 11,129 | 10,504 | 13,110 | 14,593 | 16,408 | 16,222 | 19,706 | 66,929 | |
| 2,409 | 2,563 | 2,523 | 2,711 | 2,734 | 3,023 | 2,734 | 3,336 | 3,466 | 3,802 | 3,510 | 3,819 | 14,597 | |
| 1,688 | 1,810 | 1,836 | 2,003 | 1,984 | 2,309 | 2,362 | 2,648 | 2,741 | 3,344 | 2,934 | 3,430 | 12,448 | |
| 4,098 | 4,372 | 4,359 | 4,714 | 4,719 | 5,331 | 5,096 | 5,984 | 6,206 | 7,633 | 7,372 | 10,728 | 31,939 | |
| 3,541 | 3,193 | 2,736 | 4,419 | 4,550 | 5,798 | 5,408 | 7,126 | 8,386 | 8,775 | 8,850 | 8,978 | 34,989 | |
| 125 | 138 | 180 | 184 | 193 | 225 | 244 | 249 | 180 | 123 | 332 | 345 | 980 | |
| 427 | 2,509 | 2,536 | 3,517 | 1,588 | 5,039 | 3,456 | 6,776 | 7,232 | 8,265 | 8,850 | 9,247 | 33,594 | |
| 485 | 319 | 293 | 550 | 618 | 629 | 697 | 1,116 | 1,650 | 1,629 | 1,454 | 2,152 | 6,885 | |
| -57 | 2,190 | 2,243 | 2,967 | 970 | 4,410 | 2,759 | 5,661 | 5,583 | 6,636 | 7,396 | 7,095 | 26,710 | |
| 963 | 3,035 | 3,116 | 4,115 | 2,248 | 5,748 | 4,163 | 7,504 | 7,882 | 8,388 | 9,691 | 9,247 | 35,208 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.